Advertisement

Reactions Weekly

, Volume 1744, Issue 1, pp 223–223 | Cite as

Pentostatin/vemurafenib

Infections, neutropenia and off-label use of vemurafenib: 3 case reports
Case report
  • 10 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective chart review, three men aged 36−52 years were described, who developed acute cholecystitis and sepsis, cellulitis and septic shock or rhinovirus and viridans group streptococci infections during treatment with pentostatin [route not stated; not all dosages stated]. All the patients additionally developed neutropenia and also received off-label treatment with vemurafenib for classic hairy cell leukaemia (c-HCL).

Case 1: A 52-year-old man developed acute cholecystitis and sepsis during treatment with pentostatin. The man, who was diagnosed with c-HCL and BRAF p.V600E mutation. He started receiving treatment with pentostatin 4 mg/m2. During the second cycle, his absolute neutrophil count decreased from 0.526×109/L to 0×109/L. His pentostatin therapy dose...

Reference

  1. Shenoi DP, et al. Classic hairy cell leukemia complicated by pancytopenia and severe infection: A report of 3 cases treated with vemurafenib. Blood Advances 3: 116-118, No. 2, 22 Jan 2019. Available from: URL: http://doi.org/10.1182/bloodadvances.2018027466 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations